Clinical trial
A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
NCT00891878 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2009
- Completion date
- January 31, 2013
- Enrollment
- 12 (actual)
- Sites
- 182
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma of the gastroesophageal junction, esophageal cancer